Terms: = Ovarian cancer AND CIC, ENSG00000079432, 23152, Q96RK0, KIAA0306 AND Treatment
5 results:
1. A putative role for ALDH inhibitors and chemoprevention of BRCA-mutation-driven tumors.
McGonigal S; Wu R; Grimley E; Turk EG; Zhai Y; Cho KR; Buckanovich RJ
Gynecol Oncol; 2023 Sep; 176():139-146. PubMed ID: 37535994
[TBL] [Abstract] [Full Text] [Related]
2. Critical role of Wnt/β-catenin signaling in driving epithelial ovarian cancer platinum resistance.
Nagaraj AB; Joseph P; Kovalenko O; Singh S; Armstrong A; Redline R; Resnick K; Zanotti K; Waggoner S; DiFeo A
Oncotarget; 2015 Sep; 6(27):23720-34. PubMed ID: 26125441
[TBL] [Abstract] [Full Text] [Related]
3. cancerous ovarian stem cells: obscure targets for therapy but relevant to chemoresistance.
Ahmed N; Abubaker K; Findlay J; Quinn M
J Cell Biochem; 2013 Jan; 114(1):21-34. PubMed ID: 22887554
[TBL] [Abstract] [Full Text] [Related]
4. Acute phase reactants and circulating immune complexes in patients with ovarian carcinoma.
Dobryszycka W; Gerber J; Zuwała-Jagiełło J; Ujec M
Arch Immunol Ther Exp (Warsz); 1991; 39(1-2):41-50. PubMed ID: 1725104
[TBL] [Abstract] [Full Text] [Related]
5. Levels of circulating immune complexes in patients with ovarian cancer.
Clarke AG; Vasey DP; Symonds EM; Faratian B; McLaughlin PJ; Price MR; Baldwin RW
Br J Obstet Gynaecol; 1982 Mar; 89(3):231-7. PubMed ID: 7066260
[TBL] [Abstract] [Full Text] [Related]
